| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 24.680 | 31.942 | 24.117 | 21.241 | 31.134 | 15.834 | 14.238 | 5.418 | 7.472 | 6.901 |
| Total Income - EUR | 24.794 | 31.942 | 24.117 | 25.539 | 31.134 | 15.834 | 14.238 | 5.418 | 7.472 | 6.910 |
| Total Expenses - EUR | 16.797 | 15.379 | 14.166 | 8.753 | 6.069 | 6.165 | 8.542 | 4.102 | 8.840 | 8.147 |
| Gross Profit/Loss - EUR | 7.997 | 16.563 | 9.951 | 16.786 | 25.065 | 9.669 | 5.697 | 1.317 | -1.368 | -1.237 |
| Net Profit/Loss - EUR | 7.253 | 15.605 | 9.228 | 16.020 | 24.131 | 9.194 | 5.321 | 1.157 | -1.419 | -1.237 |
| Employees | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Genegyn Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 34.324 | 21.014 | 7.919 | 0 | 0 | 0 | 2.502 | 4.577 | 6.007 | 5.495 |
| Current Assets | 3.230 | 3.443 | 6.166 | 9.508 | 33.450 | 11.442 | 12.355 | 1.505 | 1.677 | 466 |
| Inventories | 299 | 60 | 0 | 0 | 303 | 191 | 691 | 374 | 44 | 126 |
| Receivables | 0 | 2.048 | 747 | 8.684 | 17.472 | 7.217 | 11.082 | 692 | 78 | 267 |
| Cash | 2.931 | 1.335 | 5.419 | 824 | 15.674 | 4.034 | 582 | 440 | 1.555 | 73 |
| Shareholders Funds | -32.325 | -16.390 | -6.885 | 9.262 | 33.214 | 9.690 | 14.796 | 1.644 | 220 | -1.019 |
| Social Capital | 450 | 445 | 438 | 430 | 421 | 413 | 404 | 406 | 404 | 402 |
| Debts | 69.878 | 40.847 | 20.969 | 246 | 236 | 1.752 | 60 | 4.438 | 7.465 | 7.202 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Genegyn Srl